Steve Grun MNDL BIO CEO and co-founder (company pic)
New Israeli startup MNDL Bio is helping to unlock the full potential of engineered biology, also known as synthetic biology, paving the way for groundbreaking innovations across various fields by optimizing gene expression. The company has raised $2 million in seed funding to break into what it says is a $116 billion industry.
Precedence Research reported that the global synthetic biology market size was estimated at $16.35 billion in 2023 and is expected to hit around $148.93 billion by 2033, poised to grow at a CAGR (compound annual growth rate) of 25% between 2024 and 2033. The U.S. synthetic biology market was valued at $4.81 billion in 2023.
MNDL Bio is an Israeli synthetic biology startup that aims to revolutionize the field of gene expression optimization. Founded in 2023, the company leverages advanced computational models and machine learning algorithms to rapidly recode target genes for maximum gene expression in host organisms.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
MNDL Bio’s platform utilizes AI to analyze and optimize genes for improved performance. The company’s technology enables significantly faster development times compared to traditional methods. MNDL Bio’s solutions can lead to up to 200-fold improvements in protein production. The company’s approach can help reduce costs associated with gene expression optimization.
According to BioSpace, the synthetic biology market is experiencing rapid growth driven by its diverse applications across medicine, manufacturing, and agriculture. Through the engineering of organisms to possess novel abilities, researchers and companies worldwide are leveraging nature’s potential to address pressing challenges. Common objectives include the production of valuable substances like medicines or fuels and the enhancement of environmental sensing capabilities. In synthetic biology projects, scientists construct DNA sequences, incorporating existing genes or entirely novel ones, and integrate them into organisms’ genomes.
“Our patented models and algorithms empower companies to transition from a trial-and-error paradigm to a precise engineering approach using cutting-edge AI and deep learning models. By integrating our technology into existing R&D pipelines, companies can significantly accelerate development timelines, reduce costs, and increase the probability of success,” MNDL told Calcalist.
